SCHEMBL1785458

SCHEMBL1785458

COC(=O)c1cc([N+](=O)[O-])c(F)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TDP1 Q9NUW8 1/20 0.47
PDGFRB P09619 1/20 0.47
FGFR1 P11362 1/20 0.47
PDGFRA P16234 1/20 0.47
FLT1 P17948 1/20 0.47
FGFR3 P22607 1/20 0.47
KDR P35968 1/20 0.47
KDM4E B2RXH2 1/20 0.46
GUSB P08236 1/20 0.45
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
GAA P10253 1/20 0.42
POLB P06746 2/20 0.42
APEX1 P27695 1/20 0.42
LMNA P02545 4/20 0.42
MAPT P10636 2/20 0.41
SIRT6 Q8N6T7 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336950 0.88 TDP1 (0.47) MEN1KMT2ATDP1PDGFRBFGFR1
SCHEMBL32659715 0.87 PDGFRB (0.51) MEN1KMT2ATDP1PDGFRBFGFR1
SCHEMBL2247382 0.86 PDGFRB (0.50) MEN1KMT2ATDP1PDGFRBFGFR1
SCHEMBL1786813 0.86 MEN1 (0.51) MEN1KMT2ATDP1PDGFRBFGFR1
SCHEMBL2903296 0.86 TDP1 (0.53) MEN1KMT2ATDP1PDGFRBFGFR1
SCHEMBL24152418 0.84 CRHBP (0.44) MEN1KMT2AGUSBNPC1RAB9A
SCHEMBL3064007 0.84 LMNA (0.53) KMT2AGUSBNPC1GAAPOLB
SCHEMBL10381873 0.84 POLB (0.42) MEN1KMT2ATDP1GUSBNPC1
SCHEMBL31575920 0.83 PDGFRB (0.48) MEN1KMT2ATDP1PDGFRBFGFR1
SCHEMBL1788077 0.83 PDGFRB (0.55) MEN1KMT2ATDP1PDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119390577-A Continuous preparation process of 2-chloro-4-fluoro-5-nitrobenzoic acid methyl ester 苏利(宁夏)新材料科技有限公司 2025-02-07 CN claimed
CN-117486818-A N-phenyl thiotriazinone derivative and preparation method and application thereof 贵州大学 2024-02-02 CN claimed
EP-4225739-B1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
EP-4081521-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2025-12-10 EP disclosed
EP-4567029-A1 METHOD FOR PREPARING URACIL COMPOUND CONTAINING CARBOXYLATE FRAGMENT Jiangsu Flag Chemical Industry Co., Ltd. (CN) 2025-06-11 EP disclosed
US-20250179030-A1 METHOD FOR PREPARING A URACIL COMPOUND CONTAINING A CARBOXYLATE FRAGMENT JIANGSU FLAG CHEMICAL INDUSTRY CO., LTD. (CN) 2025-06-05 US disclosed
CN-119613399-A Tetra-substituted benzoate compound containing alkoxy acetate substituent and application thereof 江西天宇化工有限公司 2025-03-14 CN disclosed
CN-119390577-A Continuous preparation process of 2-chloro-4-fluoro-5-nitrobenzoic acid methyl ester 苏利(宁夏)新材料科技有限公司 2025-02-07 CN disclosed
CN-119390577-A Continuous preparation process of 2-chloro-4-fluoro-5-nitrobenzoic acid methyl ester 苏利(宁夏)新材料科技有限公司 2025-02-07 CN disclosed
US-20240366608-A1 PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER LUPIN LIMITED (IN) 2024-11-07 US disclosed
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2024-11-07 US disclosed
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2013-08-08 US disclosed
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 EP disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 US disclosed
CN-101883762-A Benzothiazoles as modulators of growth hormone releasing hormone receptors ASTRAZENECA AB 2010-11-10 CN disclosed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 EP disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 US disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 WO disclosed
US-4670046-A Tetrahydrophthalimide compounds, as post-emergence herbicides for use in soybean fields SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1987-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R MEN1 2250/4885KMT2A 1721/4885TDP1 4366/4885
US-20240366608-A1 PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER NRAS, KRAS, PRMT1 MEN1 625/4885KMT2A 157/4885TDP1 425/4885
US-20120115845-A1 THERAPEUTIC AGENTS GPR119, MC2R, MC4R MEN1 692/4885KMT2A 3139/4885TDP1 4230/4885
US-20250179030-A1 METHOD FOR PREPARING A URACIL COMPOUND CONTAINING A CARBOXYLATE FRAGMENT UNG, DPYD, DDT MEN1 4506/4885KMT2A 1233/4885TDP1 362/4885
US-20090186870-A1 Therapeutic Agents - 802 GPR119, SLC5A2, MC2R MEN1 1253/4885KMT2A 2304/4885TDP1 4334/4885
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER BICRA, BRD4, CNR1 MEN1 928/4885KMT2A 92/4885TDP1 2609/4885
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R MEN1 2250/4885KMT2A 1721/4885TDP1 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.